12/4
12:31 am
blte
Has Belite Bio's 134% 2025 Surge Fully Reflected Its DCF and Book Value Picture [Yahoo! Finance]
Low
Report
Has Belite Bio's 134% 2025 Surge Fully Reflected Its DCF and Book Value Picture [Yahoo! Finance]
12/3
01:15 pm
blte
Belite Bio (NASDAQ:BLTE) was given a new $187.00 price target on by analysts at BTIG Research.
Low
Report
Belite Bio (NASDAQ:BLTE) was given a new $187.00 price target on by analysts at BTIG Research.
12/3
12:05 pm
blte
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at Benchmark Co..
12/3
07:57 am
blte
Belite Bio (NASDAQ:BLTE) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
Low
Report
Belite Bio (NASDAQ:BLTE) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
12/2
05:10 pm
blte
Belite Bio (NASDAQ:BLTE) was given a new $200.00 price target on by analysts at Maxim Group.
Low
Report
Belite Bio (NASDAQ:BLTE) was given a new $200.00 price target on by analysts at Maxim Group.
12/2
07:08 am
blte
Belite Bio (NASDAQ:BLTE) was given a new $194.00 price target on by analysts at Mizuho.
Medium
Report
Belite Bio (NASDAQ:BLTE) was given a new $194.00 price target on by analysts at Mizuho.
12/1
10:37 pm
blte
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
Low
Report
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
12/1
04:26 pm
blte
Belite Bio announces proposed underwritten public offering of ADSs [Seeking Alpha]
Medium
Report
Belite Bio announces proposed underwritten public offering of ADSs [Seeking Alpha]
12/1
04:20 pm
blte
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
Medium
Report
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
12/1
02:25 pm
blte
Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript [Seeking Alpha]
Low
Report
Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript [Seeking Alpha]
12/1
12:10 pm
blte
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/1
06:00 am
blte
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
High
Report
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
11/24
09:23 am
blte
Belite Bio (NASDAQ:BLTE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $154.00 price target on the stock.
Medium
Report
Belite Bio (NASDAQ:BLTE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $154.00 price target on the stock.
11/20
08:43 am
blte
Belite Bio (NASDAQ:BLTE) is now covered by analysts at Mizuho. They set a "neutral" rating and a $105.00 price target on the stock.
Medium
Report
Belite Bio (NASDAQ:BLTE) is now covered by analysts at Mizuho. They set a "neutral" rating and a $105.00 price target on the stock.
11/17
01:42 pm
blte
Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight [Yahoo! Finance]
Low
Report
Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight [Yahoo! Finance]
11/15
06:41 am
blte
Belite Bio (BLTE): Exploring Valuation Following Recent Share Price Surge [Yahoo! Finance]
Low
Report
Belite Bio (BLTE): Exploring Valuation Following Recent Share Price Surge [Yahoo! Finance]
11/15
01:42 am
blte
11/11
12:30 am
blte
Belite Bio Inc (BLTE) Q3 2025 Earnings Call Highlights: Clinical Trials Progress and Financial ... [Yahoo! Finance]
Medium
Report
Belite Bio Inc (BLTE) Q3 2025 Earnings Call Highlights: Clinical Trials Progress and Financial ... [Yahoo! Finance]
11/10
06:14 pm
blte
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
03:35 pm
blte
Belite Bio GAAP EPS of -$0.28 beats by $0.20 [Seeking Alpha]
Low
Report
Belite Bio GAAP EPS of -$0.28 beats by $0.20 [Seeking Alpha]
11/10
08:46 am
blte
Belite Bio GAAP EPS of -$0.28 [Seeking Alpha]
Medium
Report
Belite Bio GAAP EPS of -$0.28 [Seeking Alpha]
11/10
08:00 am
blte
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Medium
Report
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
11/3
08:00 am
blte
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
Medium
Report
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
11/2
09:00 am
blte
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
Medium
Report
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
10/31
10:27 am
blte
Belite Bio (NASDAQ:BLTE) had its price target raised by analysts at Benchmark Co. from $80.00 to $132.00. They now have a "buy" rating on the stock.
Medium
Report
Belite Bio (NASDAQ:BLTE) had its price target raised by analysts at Benchmark Co. from $80.00 to $132.00. They now have a "buy" rating on the stock.